New hope for advanced breast cancer patients in asia: experimental drug trial shows promise

NCT ID NCT04639986

Summary

This study compares an experimental drug called sacituzumab govitecan against standard chemotherapy options for Asian patients with advanced breast cancer that has spread and stopped responding to at least two prior chemotherapy treatments. The trial aims to see if the new drug can help patients live longer without their cancer getting worse. About 330 participants will be randomly assigned to receive either the experimental drug or one of several standard chemotherapy treatments chosen by their doctor.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Tumor Hospital of Xinjiang Medical University

    Ürümqi, China

  • Ajou University Hospital

    Suwon, South Korea

  • Anhui Provincial Hospital

    Hefei, China

  • Asan Medical Center

    Seoul, South Korea

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, China

  • Chang Gung Memorial Hospital, Linkou

    Taoyuan District, Taiwan

  • Changhua Christian Medical Foundation Changhua Christian Hospital

    Changhua, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Chinese PLA General Hospital

    Beijing, China

  • Chongqing University Cancer Hospital

    Chengdu, China

  • Dong-A University Hospital

    Busan, South Korea

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Jilin Cancer Hospital

    Changchun, China

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Korea University Anam Hospital

    Seoul, South Korea

  • Linyi Cancer Hospital

    Linyi, China

  • Nanjing Drum Tower Hospital

    Nanjing, China

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Peking University People's Hospital

    Beijing, China

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Shandong Cancer Hospital

    Jinan, China

  • Shanghai General Hospital

    Shanghai, China

  • Sir Run run Shaw hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Sun Yat Sen Memorial Hospital of Sun Yat sen University

    Guangzhou, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Hospital of Jilin University

    Changchun, China

  • The second Hospital of Anhui Medical University

    Hefei, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China

  • Tri-Service General Hospital

    Taipei, Taiwan

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • Yunnan Cancer Hospital

    Kunming, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.